Trial Profile
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Rindopepimut (Primary) ; Keyhole limpet haemocyanin; Sargramostim; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Registrational; Therapeutic Use
- Acronyms ACT-IV
- Sponsors Celldex Therapeutics Inc
- 06 Apr 2022 This trial has been completed in Netherland (End Date: 15 Apr 2016), according to European Clinical Trials Database record.
- 22 Aug 2017 Primary endpoint (Overall Survival) has not been met as per the results published in the Lancet Oncology
- 22 Aug 2017 Results published in the Lancet Oncology